455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Reports Fourth Quarter and Full Year 2025 Financial Results
Announces Pricing of Upsized $400 Million Public Offering
Nektar Therapeutics Reports $229.1 Million in Cash and Investments
Investor Presentation
News
Chief Legal Officer Departure - Mark A. Wilson Steps Down at Nektar
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership